Brief: Bioporto Announces Preliminary Results For 2023

BioPorto A/S

22/02/2024 07:15

Feb 22 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * BIOPORTO ANNOUNCES PRELIMINARY RESULTS FOR 2023 AND
PROVIDES
STRATEGIC UPDATE FOR THE PERIOD 2024-2026
    * PRELIMINARY CALENDAR YEAR 2023 RESULTS SHOW TOTAL REVENUE
OF DKK
31 MILLION (USD 4.5 MILLION), A 7% INCREASE OVER PRIOR YEAR.
    * PRELIMINARY 2023 ADJUSTED EBITDA WAS DKK (56) MILLION (USD
(8.1)
MILLION)
    * AS OF DECEMBER 31, 2023, COMPANY HAD CASH AND CASH
EQUIVALENTS
OF DKK 66 MILLION (USD 9.8 MILLION)
    * IN 2025 AND 2026, BIOPORTO PLANS TO ENGAGE IN MORE
DISTRIBUTION
PARTNERSHIPS WITH ADDITIONAL LEADING INSTRUMENT MANUFACTURERS
    * SEEKING FDA CLEARANCE FOR ADULT USE IS ESTIMATED TO
REQUIRE AN
INVESTMENT OF USD 15-20 MILLION IN PERIOD 2024-2026.
    * EXPECTED REVENUE GROWTH OF 30% IN 2024
    * IN 2024, BIOPORTO IS TARGETING TO ACHIEVE TOTAL REVENUE OF
DKK
40 MILLION (USD 6 MILLION)
    * GROWTH WILL BE DRIVEN BY INCREASED SALES OF NGAL PRODUCTS
-
PRIMARILY IN US FOLLOWING FDA CLEARANCE

Source text for Eikon:  ID:nGNE55Q5Tf 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))